Randomized, Double-blind, Placebo-controlled, Multi-center, Fixed Dose Study Designed to Evaluate the Safety and Tolerability of a Single Administration of MG01CI (Metadoxine Extended Release, MDX) in Adolescents With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2015
Price : $35 *
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Alcobra
- 10 Mar 2015 Results published in the Media Release.
- 03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Feb 2015 According to a media release, Alcobra expects to report data by the end of the first quarter of 2015.